Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for Robin L. Martin�
+0.21 (0.20%)
After Hours: 106.65 +0.08 (0.08%)
Nov 24, 7:53PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 105.50 - 106.80
52 week 85.95 - 123.37
Open 105.75
Vol / Avg. 6.55M/9.87M
Mkt cap 153.85B
P/E 9.76
Div/yield 0.43/1.61
EPS 10.92
Shares 1.44B
Beta 0.83
Inst. own 82%
Feb 1, 2016
Q4 2015 Gilead Sciences Inc Earnings Release (Estimated) - 4:05PM EST - Add to calendar
Dec 1, 2015
Gilead Sciences Inc at Piper Jaffray Healthcare Conference Add to calendar
Dec 1, 2015
Gilead Sciences Inc at Nasdaq OMX Investor Program Add to calendar
Nov 10, 2015
Gilead Sciences Inc at Credit Suisse Healthcare Conference
Oct 27, 2015
Q3 2015 Gilead Sciences Inc Earnings Call - Webcast
Oct 27, 2015
Q3 2015 Gilead Sciences Inc Earnings Release
Sep 16, 2015
Gilead Sciences Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 9, 2015
Gilead Sciences Inc at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 55.36% 48.45%
Operating margin 67.33% 61.33%
EBITD margin - 65.55%
Return on average assets 41.02% 42.13%
Return on average equity 109.50% 90.32%
Employees 7,000 -
CDP Score - -


United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Brett Pletcher Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul Rutherford Carter Executive Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Andrew Cheng M.D., Ph.D. Executive Vice President - HIV Therapeutics and Development Operations
Bio & Compensation  - Reuters
William A. Lee Ph.D. Executive Vice President - Research
Age: 56
Bio & Compensation  - Reuters
Taiyin Yang Ph.D. Executive Vice President - Pharmaceutical Development and Manufacturing
Age: 60
Bio & Compensation  - Reuters